The Ministry of Health and Family Welfare has clarified that the WHO Global Hepatitis Report 2024 is based on modeling data rather than actual surveillance figures. Viral hepatitis, particularly hepatitis B and C, remains a significant public health concern globally. According to the report, India accounts for a considerable share of the global hepatitis burden, particularly hepatitis B.
Acknowledging the seriousness of the issue, India has taken proactive measures to combat viral hepatitis through the National Viral Hepatitis Control Program (NVHCP).
During a recent Rajya Sabha session, the Minister of State for Health, Smt. Anupriya Patel, addressed questions raised by Shri Akhilesh Prasad Singh. These included whether India, as per the WHO Global Hepatitis Report 2024, ranks second globally in hepatitis cases, with 2.9 crore hepatitis B cases, and the reasons behind this prevalence. The Minister was also asked if low diagnosis and treatment rates were primary contributors to the high case numbers or whether other factors were at play. Additionally, inquiries were made regarding whether all hepatitis-infected individuals receive free treatment under the NVHCP, and if not, whether the government intends to offer universal free treatment.
In her response, the Minister clarified that the WHO Global Hepatitis Report 2024 relies on modeling rather than actual surveillance data. As per the 2023 Seroprevalence Report, developed under the National Program for Surveillance of Viral Hepatitis (NVHCP, National Health Mission), the seroprevalence of hepatitis B in India is estimated at 0.85% (95% CI: 0.85–0.86). Based on this, approximately 1.18 crore individuals are likely infected with hepatitis B.
As reported by medicaldialogues, launched in 2018, the NVHCP has been providing free treatment for hepatitis B since 2019. Diagnosis and treatment under the program are offered free of cost, based on the needs of patients undergoing treatment, the Minister added.